Abstract：
Hybridoma technology is a well-established and indispensable tool for generating high-quality monoclonal antibodies and has become one of the most common methods for monoclonal antibody production. In this process, antibody-producing B cells are isolated from mice following immunization of mice with a specific immunogen and fused with an immortal myeloma cell line to form antibody-producing hybridoma cell lines. Hybridoma-derived monoclonal antibodies not only serve as powerful research and diagnostic reagents but have also emerged as the most rapidly expanding class of therapeutic biologicals. In spite of the development of new high-throughput monoclonal antibody generation technologies, hybridoma technology still is applied for antibody production due to its ability to preserve innate functions of immune cells and to preserve natural cognate antibody paring information. In this chapter, an overview of hybridoma technology and the laboratory procedures used for hybridoma production and antibody screening of peptide-specific antibodies are presented.
摘要：
杂交瘤技术是产生高质量单克隆抗体的成熟和不可缺少的工具,并且已经成为单克隆抗体生产的最常用方法之一。在这个过程中,在用特异性免疫原免疫小鼠后,从小鼠中分离产生抗体的B细胞,并与永生骨髓瘤细胞系融合以形成产生抗体的杂交瘤细胞系。杂交瘤衍生的单克隆抗体不仅用作强大的研究和诊断试剂，而且还成为最迅速发展的治疗性生物制剂类别。尽管开发新的高通量单克隆抗体产生技术,由于杂交瘤技术能够保留免疫细胞的先天功能并保留天然同源抗体配对信息，因此仍将其应用于抗体生产。在这一章中,概述了杂交瘤技术和用于杂交瘤生产和肽特异性抗体的抗体筛选的实验室程序。
